TG Therapeutics added to Focus List at Roth Capital Roth Capital added TG Therapeutics to the Focus List based on exceptions the remainder of 2104 will be transformational with upcoming data catalysts and improved visibility from the competitive landscape. Shares are Buy rated with a $15 price target.
News For TGTX From The Last 14 Days
Check below for free stories on TGTX the last two weeks.
TG Therapeutics SPA for CLL study earlier than expected, says Ladenburg Ladenburg said TG Therapeutics reached an agreement with the FDA regarding a Special Protocol Assessment, or SPA, for a trial of its combo treatment for Chronic Lymphocytic Leukemia, or CLL, "quite ahead" of the firm's December expectation. The firm believes there is a relatively high probability for TG's combo to meet the specified primary endpoint and increased its price target on the stock to $22 from $18.